Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib in advanced and relapsed ovarian cancer
NCT04392102Phase 2Completed
- Sponsor
- Zai Lab
- Start
- Aug 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of niraparib in ovarian cancer, sponsored by Zai Lab. Primary endpoint: Objective Response Rate up to 3 years. Started Aug 2020; status: completed.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04392102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04392102.